Clinical trials: Immunoglobulin
Advanced Hepatocellular Carcinoma
Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a single-arm, open-label and exploratory clinical study of Anlotinib Hydrochloride Capsules combined with Sintilimab injection in the treatment of advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT04052152
- Testing
- Anlotinib and Sintilimab injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Kidney Transplantation
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
- Trial name
- PERSPECTIVE (NCT04803058)
- Testing
- TCD601
- Where
- 3 sites in United States, South Korea
- Volunteers
- 7 people
- Sponsor
- ITB-Med LLC
Gastric Adenocarcinoma
Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma
1. Target population: patients with resectable locally advanced proximal (including gastroesophageal junction, fundus and upper body) stomach adenocarcinoma (cT3-4aN+M0). 2.
- Trial name
- Neo-PLANET (NCT03631615)
- Testing
- Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumor
PTX-35 in Patients With Advanced Solid Tumors
A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care
- Trial name
- NCT04430348
- Testing
- PTX-35
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pelican Therapeutics, Inc.
Healthy
Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects
This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.
- Trial name
- NCT06171048
- Testing
- CM310
- Where
- China
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
Transplant Failure, Heart Transplant Rejection
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography…
- Conditions
- Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection
- Trial name
- LEONE-HT (NCT05184426)
- Testing
- Echocardiogram, Cardiac magnetic resonance, Coronary angiography
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Juan Francisco Delgado Jimenez
Diarrhea
Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I
The purpose of this study is to assess anti-CFA/I and anti-CfaE BIgG safety and to determine protective efficacy of anti-CFA/I and anti-CfaE BIgG against diarrhea after challenge with H10407, a CFA/I-expressing ETEC strain.
- Trial name
- BIgGI (NCT00435526)
- Testing
- anti-CFA/I bovine IgG, and anti-CfaE bovine IgG
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Gastric Cancer
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
For locally advanced gastric cance, neoadjuvant chemotherapy can increase the resectability of tumor, and finally improve the long-term survival.
- Trial name
- NCT04367025
- Testing
- Camrelizumab, Oxaliplatin, S1
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese PLA General Hospital
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects.
- Trial name
- ICE (NCT00220740)
- Testing
- Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 117 people
- Sponsor
- Grifols Therapeutics LLC
Kidney Transplantation
Effect of BM-MSCs on Chronic AMR After Kidney Transplantation
This study is designed to investigate the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) on chronic antibody-mediated rejection (cAMR) after kidney transplantation.
- Trial name
- NCT02563340
- Testing
- BM-MSCs, Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Rabies Human
To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)
To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.
- Trial name
- rabies (NCT06177249)
- Testing
- Control vaccine, Experimental vaccine
- Where
- China
- Volunteers
- 1,956 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Cholangiocarcinoma, Intrahepatic, PD-L1
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
The study aims to evaluate the efficacy and safety of PD-L1 antibody combined with the CTLA-4 antibody in patients with advanced ICC who progressed after standard treatment.
- Conditions
- Cholangiocarcinoma, Intrahepatic, PD-L1, CTLA4
- Trial name
- NCT04634058
- Testing
- PD-L1 antibody combined with CTLA-4 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Pyrexia
Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy
The study examines the development of fever after administration of Actemra (tocilizumab) in patients who have fever and other cytokine release symptoms (headache, nausea, palpitations, low blood pressure) due to cancer therapy…
- Trial name
- Nov IIT- Pyrex (NCT04652258)
- Testing
- Actemra
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Multiple Myeloma
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.
- Trial name
- NCT00079716
- Testing
- SGN-40 (anti-huCD40 mAb)
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Seagen Inc.
Advanced Gastrointestinal Tumors
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors.
- Trial name
- NCT01916447
- Testing
- TAS-102, CPT-11, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Taiho Oncology, Inc.
Acute Otitis Media
Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children
This clinical study is designed to assess prospectively the sero-responses to various proteins in cases of pneumococcal Acute Otitis Media.
- Trial name
- NCT01214538
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- NasVax Ltd
Amyloidosis, Immunoglobulin Light Chain Deposition
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
This phase II trial studies how well ibrutinib with or without bortezomib and dexamethasone works in treating patients with immunoglobulin light chain amyloidosis that has come back after a period of improvement or that does not…
- Trial name
- NCT03130348
- Testing
- Bortezomib, Dexamethasone, Ibrutinib
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell…
- Trial name
- NCT00854308
- Testing
- Erlotinib HCl, MetMAb
- Volunteers
- 137 people
- Sponsor
- Genentech, Inc.
Gastric Adenocarcinoma
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
The goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two…
- Trial name
- DTP-HER2 (NCT07507526)
- Testing
- Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.